Načítá se...
Varenicline, Smoking Cessation and Neuropsychiatric Adverse Events
OBJECTIVE: In 2009 FDA issued a black box warning for varenicline and neuropsychiatric events. We studied efficacy (smoking cessation) of varenicline, and safety (neuropsychiatric events) in both randomized clinical trials (RCTs) and a large observational study. The observational study was included...
Uloženo v:
| Vydáno v: | Am J Psychiatry |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4238282/ https://ncbi.nlm.nih.gov/pubmed/24030388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1176/appi.ajp.2013.12121599 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|